Indian markets are closely monitoring several key stocks on August 24, with pharmaceutical companies Caplin Point Laboratories and Natco Pharma facing recent regulatory scrutiny. Meanwhile, industrial heavyweights Mahindra & Mahindra and Grasim Industries are making headlines with significant expansion plans. Reliance Industries and the broader real estate sector also remain in focus due to recent corporate actions and market trends.
Pharma Companies Under Watch
Caplin Point Laboratories saw its shares decline by 2.38% on August 24 after its subsidiary received a Form 483 from the U.S. Food and Drug Administration (USFDA). The inspection, conducted from August 13 to August 21, 2026, at its injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu, resulted in 10 observations. The company clarified that these observations were procedural and did not involve data integrity issues. It also noted that none of the observations were repeat findings.[business-standard+3]
Despite the regulatory setback, Caplin Point reported strong financial results for the first quarter of fiscal year 2027, which ended June 30, 2026. The company's consolidated net profit surged by 18.79% year-on-year, reaching Rs 176.91 crore. Net sales also saw a robust increase of 19.63%, rising to Rs 610.36 crore compared to Rs 510.22 crore in the same quarter last year. Earnings per share (EPS) grew by 15.8% to Rs 23.27.However, investor enthusiasm was tempered as shares declined by 6.3% on August 12, following disclosures that key facilities are operating near full capacity and are booked out until February 2027, indicating potential near-term growth bottlenecks.The company also announced a dividend of Rs 4.0 per share on August 12, with a record date set for September 18, 2026.[business-standard+7]
Natco Pharma is also under scrutiny, as the USFDA issued a Form 483 with four observations following an inspection of its finished dosage formulations (FDF) unit in Hyderabad. The inspection took place between August 17 and August 21, 2026.Earlier in August, Natco Pharma presented its first quarter fiscal year 2027 results, reporting a 43% year-over-year drop in consolidated revenue to INR 7,944 million (Rs 794.4 crore). This decline was primarily attributed to lower sales of lenalidomide (REVLIMID).Despite the revenue contraction, the company's EBITDA margin improved significantly to 30.9% from 25.1% in the previous quarter, indicating enhanced operational efficiency. Profit after tax reached INR 2,065 million (Rs 206.5 crore) with a 26% margin.[tradingview+8]
Analysts have revised their revenue forecasts for Natco Pharma for 2027, projecting a 7.2% decline to Rs 32.3 billion, with statutory earnings per share expected to drop 34% to Rs 42.29.However, analysts reconfirmed a price target of Rs 1,004, suggesting that the weaker revenue expectations might not materially impact the company's market value.On a positive note, Natco Pharma received tentative USFDA approval for Olaparib Tablets (100 mg and 150 mg) on July 20, 2026. This generic version of AstraZeneca's Lynparza had estimated U.S. sales of approximately $1.4 billion for the 12 months ending March 2026. Natco will manufacture the product, while Alembic Pharmaceuticals will handle its distribution in the U.S.Additionally, in June 2026, Natco Pharma, in partnership with Lupin, secured USFDA approval for Eribulin Mesylate Injection, a generic equivalent to Eisai Inc.'s Halaven, which had estimated annual U.S. sales of $43.7 million.The company also expanded its stake in South African pharmaceutical firm Adcock Ingram Holdings to 49% in July 2026.[simplywall+8]
Industrial Giants Chart Growth
Mahindra & Mahindra (M&M) is poised for significant global expansion, particularly in the electric vehicle (EV) segment, following a strong financial year 2026. The automotive major reported a consolidated Profit After Tax (PAT) of INR 170.99 billion, marking a 35% increase over the previous year. Consolidated revenue climbed 25% to INR 1,986 billion. The company sold 1.11 million units, a 19% rise, with tractor sales growing by 24% to 526,403 units.[motoring-trends]
M&M plans a disciplined, phased entry into international EV markets, starting with right-hand-drive countries within the next 18 months.The company has an ambitious roadmap to launch 10 new internal combustion engine (ICE) SUVs and 6 new Battery Electric Vehicles (BEVs) by 2031.To meet growing demand, M&M increased its SUV ICE capacity from 54,000 units to 56,500 units per month by the end of FY2026, with plans to reach 60,000 units. Its BEV capacity also expanded from 5,000 units per month in FY2025 to 8,000 units per month by March 31, 2026.The company is targeting an 18-20% EV penetration rate over the next five years. Monthly production for its popular XEV 9S model is expected to increase from 6,000 to 8,000 units this year, with a total EV capacity target of 12,000 to 14,000 units per month by fiscal year 2028.M&M expects tractor sales to grow in the mid-single digits and SUV sales to see mid-to-high teen growth in FY2027.[motoring-trends+4]
Grasim Industries, a flagship company of the Aditya Birla Group, is targeting consolidated revenue of Rs 2 lakh crore in fiscal year 2026-27. This ambitious goal represents an almost doubling of its top line in five years, driven by expansion into new sectors like paints, digital commerce, financial services, and renewable energy.The company reported a record consolidated revenue of Rs 1.75 lakh crore in FY2026.[businessworld+2]
A significant investment of ₹3,094 crore was announced in June 2026 for Phase II of its Lyocell capacity expansion at Harihar, Karnataka. This expansion will add 110,000 tonnes per annum (TPA) and, combined with the 55,000 TPA Phase I plant currently under construction, will bring Grasim's total Lyocell capacity to nearly 210,000 TPA. This positions Grasim as one of the largest Lyocell producers globally. Phase I is slated for commissioning by mid-2027, with Phase II lines expected in 2028 and 2030. Grasim's new growth engines are rapidly scaling up. Birla Opus, its decorative paints business, doubled its revenue year-on-year in FY2026 and achieved a 10% standalone revenue market share in India's decorative paints market within two years of launch. Its B2B e-commerce platform, Birla Pivot, exceeded its annual revenue target of Rs 8,500 crore ahead of schedule. Additionally, Aditya Birla Renewables has expanded its capacity visibility to around 10 GW, with an ambition to reach 20 GW and beyond in the coming years. Shareholders approved all resolutions at the company's 79th Annual General Meeting on August 21, 2026. The company also declared a dividend of Rs 10 per share for the year ended March 31, 2026, with an effective date of August 7, 2026. On August 24, Grasim Industries was trading at Rs 3292.7, with a market capitalization of Rs 223842.95 crore.[grasim+10]
Reliance and Real Estate in Focus
Reliance Industries Limited (RIL) shares were under pressure in early trade on August 24, following MSCI's announcement of changes to its India index as part of its August 2026 review. However, shareholders had approved three key resolutions with the required majority on August 20, 2026. These resolutions included proposals for material related-party transactions involving RIL and its subsidiaries. They also expanded the company's objects clause to encompass the production, processing, sale, and distribution of ammonium nitrate, explosives, blasting agents, fertilizers, and agro-chemicals. RIL's stock has shown significant momentum, delivering a 14.96% return in the last month and an impressive 47.13% in the last three months as of August 13, 2026. On August 24, RIL's last traded price was 1311.2, with a market capitalization of 1777228.31 crore.[facebook+3]
The Indian real estate sector continues to attract investor attention in August 2026, driven by strong housing demand, the launch of premium projects, and record office leasing activity. Institutional investment into Indian real estate reached ₹27,045 crore in Q2 CY2026, representing a 70% year-on-year increase. The first half of 2026 recorded ₹41,566 crore in investments, marking the strongest first half in six years.[m+1]
Several prominent real estate stocks are being closely watched. DLF Ltd, India's largest listed real estate developer, maintains a strong luxury housing pipeline and saw an increase in Q1 FY27 PAT despite deferred project launches. Brokerages remain positive on its H2 FY27 growth. Godrej Properties is noted for its industry-leading residential sales bookings and a robust pan-India launch pipeline, supported by an asset-light expansion strategy. Prestige Estates Projects, with its strong residential and commercial portfolio, is expanding beyond South India and is a top pick for some brokerages like Nomura. Oberoi Realty, a premium Mumbai-focused developer, benefits from a strong balance sheet and resilient luxury segment. LodhaDevelopers, one of India's largest residential developers, shows healthy presales and execution, expanding its presence in Mumbai, Pune, and Bengaluru. Analysts emphasize focusing on companies with strong cash flows, low leverage, and robust launch pipelines within this dynamic sector.[venturasecurities+7]
The diverse activities across these sectors highlight the dynamic nature of the Indian market on August 24, with regulatory challenges in pharma contrasted by significant expansion and growth targets in manufacturing and real estate.[facebook]
